BackBiocept Overview

Biocept Receivables

Biocept's receivables is $800K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$800000.00
↓ 95.40% YoYΔ $-16.58M vs prior year quarter

Peer average

Loading

Biocept Receivables History

Loading

Biocept vs. peers: Receivables Comparison

Loading

Biocept Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biocept (BIOC) FAQ

As of the most recent data (June 2023), BIOC shows a receivables of $800K. That compares with $17M in the prior-year period — down 95.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BIOC's receivables is now $800K (was $17M) — a 95.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biocept is outperforming or lagging.

Tracking BIOC's receivables over time shows whether Biocept is scaling, shrinking, or reshaping that part of the business. The current reading is $800K That compares with $17M in the prior-year period — down 95.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Biocept's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $800K) with ownership activity and broader fundamentals.

Biocept's receivables is $800K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.